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Abstract: After multiple positive studies, gemcitabine, approved for the treatment of pancreas cancer by the FDA in 1977, 
became standard of care. Whether this therapeutic advance has translated into longer survival for pancreas cancer patients 
in general has not been established. This study, derived from SEER (Surveillance, Epidemiology, and End Results (SEER) 
Program of the National Cancer Institute) data, compared the survival experiences of the gemcitabine (1998–2004) and 
pre-gemcitabine (1988–1997) eras for 7,151 patients who had metastatic disease and did not undergo extirpative surgery, 
14,369 patients who had not undergone surgery and had metastases, 5,042 patients who had undergone surgery and did not 
have metastases, and 5,011 patients who had undergone surgery and had metastases. Calculated survival time ratios (TR) 
were adjusted for radiotherapy history, grade, nodal status, loco-regional extent of disease, age, race, and gender. For those 
who did not undergo extirpative surgery, improvements in survival in the gemcitabine era (1998–2004) versus the prior 
time period (1988–1997) seen for patients with metastatic cancer (TR = 1.20, 95% c.i. 1.15–1.25) were not seen for those 
without metastatic cancer (TR = 1.05, 95% c.i. 1.00–1.15). For those who did undergo extirpative surgery, improvements 
were much more dramatic for those with metastatic cancer (TR = 1.61, 95% c.i. 1.45–1.80) than those without metastases 
(TR = 1.23, 95% c.i. 1.15–1.31). The results are consistent with the notion that the promising ﬁ  ndings with respect 
to gemcitabine in the controlled clinical trials have found expression in the general population of patients with pancreas 
cancer.
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Background
Pancreas cancer is a common cancer that is commonly lethal, being the fourth leading site for cancer 
deaths for both men and women. (Jemal, Siegel et al. 2008) After the results of Burris, et al., (Burris, 
Moore et al. 1997) were published, FDA approval in 1997 for gemcitabine as a chemotherapeutic agent 
to treat metastatic pancreas cancer followed. Studies supporting the efﬁ  cacy of this agent (Rothenberg, 
Moore et al. 1996; Burris and Storniolo, 1997; Burris, Moore et al. 1997; Rothenberg, Sharma et al. 
1998; Tempero, Plunkett et al. 2003; Burris, 2005; Ko, Dito et al. 2006; Gansauge, Ramadani et al. 
2007) proved so positive that single agent gemcitabine therapy is now standard of care, (Burris, 2005) 
rendering justiﬁ  ed the designation of the years 1988–2007 as the gemcitabine era. Whether this thera-
peutic advance has translated into longer survival for pancreas cancer in general, however, has not been 
established. We hypothesized that analyzing survival differences between the gemcitabine and the pre-
gemcitabine era might shed light on this question, provided separate analyses were performed on patients 
with and without metastases, separating patients into those who had and had not undergone surgery. As 
a source of general information concerning cancer patients in the United States, the Surveillance, Epi-
demiology, and End Results (SEER) Program of the National Cancer Institute is unparalleled because 
it collects and publishes cancer incidence and survival data from 14 population-based cancer registries 
and three supplemental registries covering approximately 26% of the US population. (National Cancer 
Institute, 2008).
This study compared survival during the gemcitabine era with that of the pre-gemcitabine era for 
evaluated for 7,151 patients metastatic disease and did not undergo extirpative surgery (group 1), 14,369 406
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patients who had not undergone surgery and had 
metastases (group 2), 5,042 patients who had 
undergone surgery and did not have metastases 
(group 3), and 5,011 patients who had undergone 
surgery and had metastases (group 4). Survival 
ratios were adjusted for an array of potentially 
confounding variables. Results of the analysis were 
then used to subdivide the study population to 
provide empirical median survival estimates for 
the gemcitabine era stratiﬁ  ed by surgical status, 
the history of radiotherapy, and nodal status.
Materials and Methods
A case listing session was performed using the 
Surveillance and End Results 17 Registries 
Limited-Use, November 2006 sub (1973–2004 
varying) database. Patients were excluded if they 
were recorded as having been dead or lost to fol-
low-up at the time of diagnosis, if the tumor was 
not microscopically conﬁ  rmed, if it was not known 
whether or not the patient had metastatic tumor, if 
the behavior was not listed as being malignant, if 
it was not known whether or not the patient had 
had surgery, if the patients were of unknown race 
or age, if the ICD code was other than 8140, 8141, 
8480, 8481, or 8489, if the site of origin was listed 
as being other than as listed below, if the diagnosis 
was rendered before 1988, or if a prior cancer had 
been diagnosed. Explanatory variables considered 
were: 1) surgery—extirpative surgery versus not; 
metastatic disease—present versus absent; year of 
diagnosis: after gemcitabine approval (1998–2004) 
versus before (1988–1997); 2) radiation therapy—
provided versus not provided versus unknown; 3) 
grade—high (grades III and IV) versus low (grades 
I and II) versus ungraded; 4) loco-regional extent—
confined to pancreas versus extended beyond 
pancreas versus unknown; 5) nodal status—posi-
tive versus negative versus unknown; 6) origin 
within pancreas—head versus body, tail, or over-
lapping versus pancreas, not otherwise speciﬁ  ed; 
7) age—at or above median 68 years old versus 
younger; 8) race—White versus Black versus 
Other; and 9) gender.
The intent was to determine if the effect of 
gemcitabine might be evident in survival patterns 
of patients with pancreas cancer. To this end, four 
separate analyses calculated adjusted survival time 
ratios for each of the subsets, group 1, group 2, 
group 3, and group 4. Cox proportional hazards 
and Rayleigh, lognormal, loglogistic, Weibull, and 
exponential accelerated failure time models were 
considered as means to analyze survival experi-
ence. Because lognormal regression had the lowest 
overall AIC (Aikake’s an Information Criterion) 
value, it was used to estimate adjusted ratios of 
survival times and 95% conﬁ  dence intervals. Log 
rank tests were used for univariate comparisons. 
Kaplan-Meier methods were used to calculate 
median survivals and 95% conﬁ  dence intervals. 
Null hypotheses were rejected when P  0.05. All 
analyses were performed on R.
Results
Of  31,573 patients retrieved, 28,894 (91.5%) died, 
with a median survival of ﬁ  ve months. Table 1 
displays distributions of patients and deaths, as 
well as median survivals, stratiﬁ  ed by the predictor 
variables. Log rank tests showed that each grouping 
demonstrated differences with respect to survival 
that could not have been explained by chance.
Figure 1 shows adjusted survival time ratios 
(TR) and 95% conﬁ  dence intervals (red bars) as 
calculated by log normal regression. Each column 
displays all comparisons of a separate analysis: the 
leftmost shows results for 7,151 patients in group 1; 
the second, for 14,369 in group 2; the third, for 
5,042 in group 3; and the fourth, for 5,011 in 
group 4. Each row shows results for all four groups 
for a comparison. Note the dotted grey lines; where 
these cross red bars, as is true for loco-regional 
extent comparisons for patients in group 4, results 
are not statistically signiﬁ  cant (P  0.05).
For those who did not undergo extirpative sur-
gery, improvements in survival in the gemcitabine 
era (1998–2004) versus the prior time period 
(1988–1997) seen for patients with metastatic 
cancer (group 2) (TR = 1.20, 95% c.i. 1.15–1.25) 
were not seen for those without metastatic cancer 
(group 1) (TR = 1.05, 95% c.i. 1.00–1.15). For 
those who did undergo extirpative surgery, 
improvements were much more dramatic for those 
with metastatic cancer (group 4) (TR = 1.61, 95% 
c.i. 1.45–1.80) than those without metastases 
(group 3) (TR = 1.23, 95% c.i. 1.15–1.31).
Compared with those who had not received 
radiation therapy, those who did had much longer 
median survivals; the lower limits of all four 95% 
conﬁ  dence intervals were above 1.5; radiotherapy 
was associated with a survival time increase of 
over 50%. As expected, having one or more lymph 
nodes with metastatic cancer yielded a shorter 407
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survival than having no lymph nodes with meta-
static cancer. Patients without lymph node sam-
pling had an even shorter survival than those who 
had negative lymph nodes.
With respect to extent of disease, differences 
with respect to the presence or absence of metas-
tases were quite prominent. Whereas only 12% of 
patients without metastases lacked information 
about loco-regional spread, 89% of patients with 
metastases did. Only 37 (0.2%) of patients with 
metastatic disease were recorded as having disease 
conﬁ  ned to the pancreas. With such numbers, it is 
unsurprising that conﬁ  dence intervals for patients 
with metastases were so wide as to preclude deﬁ  -
nite assertions about the importance of conﬁ  nement 
or lack of conﬁ  nement of the tumor to the pancreas. 
By contrast, for patients without metastases 
adjusted survival differences with respect to local 
extent of disease were deﬁ  nitely small. Apart from 
the above discussed variables, remaining TR point 
estimates were modest, ranging from 0.73 
to 1.43.
Attention was directed to differences with 
respect to surgical history, metastases, radiation 
Table 1. Characteristics of interest of pancreatic adenocarcinoma patients. For all log rank tests, P  0.01.
    Patients  Deaths  Survival in months  Log rank test
   (n  = 31,573) (n  = 28,894)  Median (95% c.i.)  χ² (d.f.)
Extirpative surgery       
  No  21,520 (68.2%)  19,918 (68.9%)  4 (4–4) 
  Yes  10,053 (31.8%)  8,976 (31.1%)  6 (6–6)  1,040 (1)
Metastases      
  No  12,193 (38.6%)  10,523 (36.4%)  9 (9–9) 
  Yes  19,380 (61.4%)  18,371 (63.6%)  3 (3–3)  4,794 (1)
Year of diagnosis       
  1988–1997  12,543 (39.7%)  12,372 (42.8%)  4 (4–4) 
  1998–2004  19,030 (60.3%)  16,522 (57.2%)  5 (5–5)  98 (1)
Radiotherapy      
  No radiotherapy administered  23,951 (75.9%)  22,289 (77.1%)  4 (4–4) 
  Radiotherapy administered  7,059 (22.4%)  6,078 (21.0%)  10 (9–10) 
  Unknown  563 (1.8%)  527 (1.8%)  5 (5–6)  2,460 (2)
Grade
  High (III or IV)  7,231 (22.9%)  6,731 (23.3%)  4 (4–4) 
  Low (I or II)  8,473 (26.8%)  7,508 (26.0%)  7 (7–7) 
  Unknown  15,869 (50.3%)  14,655 (50.7%)  4 (4–4)  1,142 (2)
Nodal status       
  Negative  2,775 (8.8%)  2,215 (7.7%)  12 (12–13) 
  Positive  4,283 (13.6%)  3,676 (12.7%)  9 (9–10) 
  Unknown  24,515 (77.6%)  23,003 (79.6%)  4 (4–4)  3,469 (2)
Loco-regional extent       
 Conﬁ  ned to pancreas  2,752 (8.7%)  2,471 (8.6%)  9 (9–9) 
  Beyond pancreas  10,097 (32.0%)  9,458 (32.7%)  8 (8–8) 
  Unknown  18,724 (59.3%)  16,965 (58.7%)  3 (3–3)  4,013 (2)
Origin      
  Head  17,159 (54.3%)  15,386 (53.2%)  6 (6–6) 
  Body, Tail, Other  8,798 (27.9%)  8,169 (28.3%)  4 (4–4) 
  Pancreas, NOS  5,616 (17.8%)  5,339 (18.5%)  3 (3–3)  1,286 (2)
Age     
  68 or Older  15,302 (48.5%)  13,742 (47.6%)  6 (6–6) 
  67 or Younger  16,271 (51.5%)  15,152 (52.4%)  4 (4–4)  470 (1)
Race      
  White  25,529 (80.9%)  23,349 (80.8%)  5 (5–5) 
  Black  3,669 (11.6%)  3,410 (11.8%)  4 (4–4) 
  Other  2,375 (7.5%)  2,135 (7.4%)  5 (5–5)  49 (2)
Gender      
  Female  15,530 (49.2%)  14,169 (49.0%)  5 (5–5) 
  Male  16,043 (50.8%)  14,725 (51.0%)  5 (5–5)  7.8 (1)408
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therapy, lymph node status, and the gemcitabine 
era. Figure 2 displays empirically derived median 
survivals in months for the years 1988–1997; 
Figure 3, for the years 1998–2004. Results were 
consistent with prior analyses. Consider the differ-
ences between eras: median survival point esti-
mates for group 1 hardly changed; that for groups 
2 and 3 showed modest increments; that for group 4 
showed dramatic increments. Among patients with 
negative or unknown nodal status, median survival 
point estimates for those who underwent surgery 
were greater than for those who did not. For posi-
tive nodes, results with respect to surgery were 
varied. Uniformly, radiotherapy was associated 
with larger and metastatic disease with smaller 
median survival point estimates. For the most part, 
patients with negative nodes had larger median 
survival point estimates than did those with posi-
tive nodes, who in turn had larger median survival 
point estimates than those with unknown nodal 
status.
Discussion
The results are consistent with the notion that the 
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  No Surgery          No Surgery         Surgery               Surgery
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Figure 1. Adjusted survival time ratios and 95% conﬁ  dence intervals (red bars), as calculated by log normal regression, for 31,573 patients with 
pancreatic adenocarcinoma. Each column represents the results of a regression analysis in which the variables evaluated for their effects on 
survival included year of diagnosis, radiotherapy, grade, nodal status, loco-regional extent, origin within the pancreas, age, race, and gender.409
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Figure 2. Empirical median survivals (95% conﬁ  dence intervals) for 12,543 patients with pancreatic adenocarcinoma diagnosed from 1988–1997.
Figure 3. Empirical median survivals (95% conﬁ  dence intervals) for 19,030 patients with pancreatic adenocarcinoma diagnosed from 1998–2004.
the controlled clinical trials have found expression 
in the general population of patients with pancreas 
cancer. Adjusted for radiotherapy history, grade, 
nodal status, loco-regional extent of disease, age, 
race, and gender, no improvement was seen in 
patients without metastatic disease who did not 
undergo surgery. With the same adjustments, the 
improvement among surgically treated patients was 410
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greater for those who had metastatic disease than 
for those who did not. Because radiotherapy tends 
to be given palliatively, the general improvement 
in survival accorded patients who underwent radio-
therapy suggests a survival beneﬁ  t that extends 
beyond a negative selection bias. Finally, a wide 
array of complex interactions exists among factors 
that are shown to affect survival, especially with 
respect to the beneﬁ  t of surgery.
After the seminal work of Burris, et al., (Burris, 
Moore et al. 1997) Food and Drug Administration 
approval was granted to gemcitabine for the treat-
ment of metastatic pancreas cancer. A wide array 
of clinical trials (Rothenberg, Moore et al. 1996; 
Burris and Storniolo, 1997; Burris, Moore et al. 
1997; Rothenberg, Sharma et al. 1998; Tempero, 
Plunkett et al. 2003; Burris, 2005; Ko, Dito et al. 
2006; Gansauge, Ramadani et al. 2007) have 
proven the efﬁ  cacy of this chemotherapeutic agent, 
such that gemcitabine’s use as single agent che-
motherapy for metastatic pancreas cancer is now 
standard of care. (Burris, 2005) For this reason, it 
is reasonable to ask whether or not the use of this 
agent has been associated with a general increment 
in survival among patients with metastatic pancreas 
cancer. The results of this study provide an afﬁ  rma-
tive answer to that question. Patients who would 
be unlikely to beneﬁ  t from gencitibine, those with-
out extirpative surgery or metastatic disease, failed 
to show an increment in survival time, when results 
were adjusted for other variables. By contrast, 
patients with metastatic surgery who had not under-
gone surgery, who would be candidates for this 
agent, showed about a 20% increase in survival, 
similar to that experienced by patients without 
metastatic cancer who had undergone surgery; 
advances in chemotherapy have, in this case, 
matched advances in surgical technique in terms 
of advancing patient survival. The Will Rogers 
effect may be partly responsible for the increased 
life expectancy seen in patients who underwent 
surgery and did not have metastatic disease. (Basu 
and Alavi, 2008) This criticism does not apply pari 
passu to patients with metastatic cancer; the 60% 
increment in survival seen in patients who had 
undergone surgery and had metastatic cancer, about 
40% more than the increment associated with 
surgery alone, occurred within the context of a 
group’s being thought to be in an equally bad state 
of affairs before or after the Will Roger’s effect 
with respect to pre-operative studies had taken 
place. Moreover, the lack of a survival increment 
for patients who had neither metastatic disease nor 
surgery militates against the existence of a Will 
Roger’s effect.
The relationship of surgery to survival is com-
plex. An array of studies have documented the 
efﬁ  cacy, safety, and underutilization of surgical 
treatment of pancreas cancer. (Imamura, Doi et al. 
2004; Lygidakis, Singh et al. 2004; Fesinmeyer, 
Austin et al. 2005; Fong, Gonen et al. 2005; 
Lygidakis, Jain et al. 2005; Mu, Peng et al. 2005; 
Kunisaki, Akiyama et al. 2006; Bilimoria, Bentrem 
et al. 2007; Bilimoria, Bentrem et al. 2007; 
Finlayson, Fan et al. 2007; Hirano, Kondo et al. 
2007; Lygidakis, Sharma et al. 2007; Reddy, Tyler 
et al. 2007; Riall and Lillemoe, 2007; Ryska, Strnad 
et al. 2007; Bruzoni, Johnston et al. 2008; Sa 
Cunha, Rault et al. 2008; Westgaard, Tafjord et al. 
2008) One randomized, controlled trial showed that, 
for localized pancreas cancer involves neither 
superior mesenteric nor common hepatic arteries, 
(Imamura, Doi et al. 2004) surgery was superior to 
chemoradiotherapy. A second trial showed that, for 
patients with advanced pancreatic head cancer with 
vascular invasion who underwent chemoimmuno-
therapy, (Lygidakis, Singh et al. 2004) resection 
was superior to palliative bypass. Far fewer resec-
tion procedures are being performed than is cur-
rently warranted. (Bilimoria, Bentrem et al. 2007; 
Riall and Lillemoe, 2007) Although safety issues 
arise with respect to older patients (Finlayson, Fan 
et al. 2007) and to hospitals that infrequently per-
form resections, (Fong, Gonen et al. 2005) the 
safety, in general, of extirpative surgery is well-
established. (Riall and Lillemoe, 2007) One study 
found surgery the most important survival factor. 
(Fesinmeyer, Austin et al. 2005) The difﬁ  culty with 
crediting surgical extirpation its survival advantage 
lies in the selection bias; patients are excluded from 
surgical extirpation if metastatic disease is known 
to be present, if the tumor does extensively invades 
blood vessels, and if the Karnovsky score is below 
70, (Wolff, Abbruzzese et al. 2008) meaning those 
who do undergo surgery are likely to do better. This 
study’s ﬁ  ndings raises the possibility that surgery’s 
advantage depends upon lymph node status moreso 
than it did on metastatic spread or radiotherapy; 
since the principal interest of this study lay in the 
effect of gemcitabine, this suggestion should be 
evaluated in a separate analysis. If this suggestion 
is confirmed, the contraindication to surgical 
extirpation by limited metastatic disease might be 
re-considered.411
Pancreas cancer survival in the gemcitabine era
Clinical Medicine: Oncology 2008:2 
With respect to radiotherapy, results of clinical 
trials have been mixed, (1987; Klinkenbijl, Jeekel 
et al. 1999; Neoptolemos, Stocken et al. 2004; 
Smeenk, de Castro et al. 2005; Stocken, Buchler 
et al. 2005; Garofalo, Regine et al. 2006; Sultana, 
Neoptolemos et al. 2006; Saif 2007; Smeenk, van 
Eijck et al. 2007; Artinyan, Hellan et al. 2008) with 
divergent opinions concerning the same study 
being published. (Klinkenbijl, Jeekel et al. 1999; 
Garofalo, Regine et al. 2006) For this reason, 
radiotherapy continues to be viewed as an option 
to be reserved for research protocols and special-
ized centers. (Wolff, Abbruzzese et al. 2008) Not-
withstanding these reservations, the present study 
found differences in survival with respect to all 
subgroups, conﬁ  rming and extending the ﬁ  ndings 
of a very recent study of node negative pancreas 
cancer using the same database. (Artinyan, Hellan 
et al. 2008) Part of the difﬁ  culty in interpreting 
these results stems from a limitation of the Surveil-
lance and End Results Database, the absence of 
information regarding the concomitant administra-
tion of chemotherapy, also noted in the prior study. 
(Artinyan, Hellan et al. 2008) For this reason, until 
the beneﬁ  t of radiotherapy is settled by clinical 
trials, radiotherapy should perhaps best be viewed 
in studies of patient databases as a variable to be 
taken into consideration in analyses of survival 
undertaken for other reasons.
Apart from its having lower absolute adjusted 
TR values than radiotherapy or nodal status, grade 
was not chosen for purposes of stratifying the 
sample into subgroups because there exists 
no consensus at this time as to which of the 
multiple grading systems for pancreas cancer 
should be used. (Cubilla, Fitzgerald et al. 1978; 
Greene, Page et al. 2002; Brennan, Kattan et al. 
2004; Adsay, Basturk et al. 2005; Compton, 
2005; Eltoum, Eloubeidi et al. 2005; Ferrone, 
Kattan et al. 2005; Johnson and Adamo, 2007) 
Although the original four grade system is still 
recognized by the American Joint Committee on 
Cancer, (Greene, Page et al. 2002) Surveillance 
Epidemiology and End Results, (Johnson and 
Adamo, 2007) and the College of the American 
Pathologists, (Compton, 2005) many do not use 
this system, preferring instead to use a three tiered 
system. (Brennan, Kattan et al. 2004; Ferrone, 
Kattan et al. 2005) The three tiered system, 
however, does have its ﬂ  aws, one of which is 
that at least one study shows that moderately 
differentiated tumors have a better prognosis than 
do well differentiated tumors; (Adsay, Basturk 
et al. 2005) the latter finding was one of the 
principle reasons grade 1 and grade 2 tumors were 
combined into a low grade category. Perhaps the 
multiplicity and complexity of grading systems in 
part induced the lack of a grade for half the 
pancreas cancer patients. A two category grading 
system has been shown to be an effective adjunct 
to the cytologic diagnosis of pancreas cancer; 
(Eltoum, Eloubeidi et al. 2005) a two grade system 
should also be considered for histologic material. 
(Adsay, Basturk et al. 2005)
Limitations of database analyses have been 
previously described, (Artinyan, Hellan et al. 2008) 
but bear some repetition. As opposed to database 
analyses, in clinical trials (Pocock, 1983) one set 
of pathologists reviews slides, one set of radiolo-
gists reviews radiographs, one set of surgeons 
performs surgery, one set of chemotherapists pro-
vides chemotherapy, and one set of radiation 
oncologists provides radiation therapy. Protocols 
are carefully followed, with deviations oft resulting 
in exclusions from the study. Patients are usually 
carefully selected to deﬁ  ne groups being compared. 
Unfortunately, as is true of assessments of radiation 
therapy in pancreas cancer, (Klinkenbijl, Jeekel 
et al. 1999; Neoptolemos, Stocken et al. 2004; 
Garofalo, Regine et al. 2006) results of controlled 
clinical trials contradict one another. Meta analyses 
(Sutton, Abrams et al. 2000; Stocken, Buchler et al. 
2005) can be performed as a means to summarize 
expert opinion and the results of published data; 
by deﬁ  nition such analyses suffer to some degree 
from the limitations of population databases. 
Clinical trials and meta analyses can not com-
pletely reﬂ  ect the world at large, where patients 
are treated by a wide array of physicians and rarely 
fall into carefully deﬁ  ned groups. Additional stud-
ies should evaluate the experience of patients in 
other nations. Because median survival of pancreas 
cancer patients is less than one half of a year, bet-
ter analyses would result from studies that record 
the number of weeks and not months of survival. 
Most important, data concerning chemotherapy 
administered to patients would greatly assist the 
analysis of their survival. This is a clinical epide-
miology study, not a clinical study in which clini-
cal parameters can be better controlled among a 
much smaller number of patients. The gain from 
using this data set with limited clinical informa-
tion lies in its representativeness and standardiza-
tion. The above limitations notwithstanding, 412
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database analyses permit one to see if beneﬁ  ts of 
carefully controlled studies have found their way 
into the population of patients at large; the present 
study provides some conﬁ  rmation that gemcitabine 
effected increases in survival of pancreas cancer 
patients with metastases.
In summary, pancreas cancer patients with 
neither metastases nor a history of surgery fared 
no better in the gemcitabine era than before, in 
contrast to those with metastases who had not 
undergone surgery. Among patients who had 
undergone surgery, those who had metastases 
showed greater improvements in survival than 
those who did not. Taken together, the results 
provide evidence for the efﬁ  cacy of gemcitabine 
as single agent therapy for metastatic pancreas 
cancer.
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